Semaphore reports $7.45M sold in equity offering after Sigmaways acquisition

Why it matters

Semaphore's $7.45M equity sale gives a young technical team capital and an operating software business, along with legacy debt, wage claims and a demanding integration job.

Semaphore Technologies, led by CEO Luke Mann and executive Ori Spector, reported selling $7.45 million of an $8 million equity offering, giving the young San Francisco technology company new financing weeks after it acquired control of software developer Sigmaways.

The Form D filed on August 12 lists five investors and $550,001 still available in the offering. Sales began on July 10, so the filing records financing activity that started about a month earlier rather than a round completed this week. Semaphore also included $250,000 of previously issued convertible securities that converted in the transaction.

Semaphore did not report a valuation, share price or investor names. The filing says no non-accredited investors participated and no commissions or finder fees were paid. It classifies Semaphore only as "Other Technology" and declines to provide a revenue range.

The filings do not describe Semaphore's product, customers, pricing or launch timing. They do show a young company pairing an equity offering with an acquisition of an operating software business.

A Stanford pair takes on an operating business

Mann and Spector worked together before Semaphore. In a 2023 Stanford natural-language-processing project, they studied style emulation with LLaMA and LoRA, a parameter-efficient model fine-tuning technique.

Stanford commencement records list Mann as a computer science graduate. Spector's personal site says he earned bachelor's and master's degrees at Stanford, worked as a product engineer at Luma AI and later became an entrepreneur-in-residence at Lux Capital. Stanford also lists Spector in the 2024 Mayfield Fellows cohort, a program centered on technology entrepreneurship.

The available sources do not explain how the founders' research relates to Semaphore or what the company plans to build.

On June 22, Semaphore acquired HeartCore Enterprises' 51% stake in Sigmaways, along with approximately $2.19 million in debt owed by Sigmaways to HeartCore. A HeartCore SEC filing describes Sigmaways as a software development operation. Earlier HeartCore filings said Sigmaways and its subsidiaries developed and sold software in the United States.

The terms show Semaphore taking control with little cash required at closing. Under the purchase agreement, Semaphore paid $1,000 upfront. HeartCore can receive an additional 10% of Sigmaways' gross revenue above $5.5 million during the following 12 months, capped at $649,000. HeartCore also transferred a $350,000 SAFE issued by Heart-Tech Health to Semaphore as part of a mutual release.

HeartCore said the price reflected uncertainty and disputes around the assets' value and collectability. The agreement also records unpaid wage, salary and compensation claims involving current and former Sigmaways employees, with those obligations assigned primarily to Sigmaways.

Martin Chow signed the purchase agreement as Semaphore's president. Mann and Spector are listed in the later Form D as executives, directors and promoters, while Mann signed as CEO.

The financing is larger than the acquisition price

Semaphore's reported equity sales dwarf the cash needed to close the Sigmaways transaction. Even if Sigmaways generates enough revenue to trigger the entire earn-out, the maximum purchase price is $650,000. That leaves most of the $7.45 million available for the company's broader operating plan, assuming the proceeds are not reserved for liabilities or other uses.

The filings do not connect the offering proceeds directly to the acquisition. The timing still makes Sigmaways central to understanding the transaction: Semaphore bought control on June 22, began selling equity on July 10 and filed the Form D on August 12.

For Mann and Spector, Sigmaways provides an established corporate operation rather than a blank-sheet startup. It also brings obligations that will require operating discipline, including disputed debt and employee compensation claims.

Semaphore was incorporated in 2026 and previously used the name Ramona, Inc., according to the Form D.

The five investors are backing a company whose filings leave its product and business model undisclosed. The founders' technical work and Spector's experience at Luma AI and Lux Capital provide some context, while the Sigmaways acquisition gives Semaphore control of a software developer that it must operate while defining its direction.

That combination makes the financing execution-heavy. Semaphore has capital, technical founders and control of a software developer, but the available filings do not say how those pieces fit together. Mann, Spector and Chow now have to show what the company will build and how Sigmaways will fit into it.